Literature DB >> 22248141

Commentary on Ling et al. (2012): The PROMETA™ treatment does not reduce methamphetamine use.

Mehmet Sofuoglu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22248141      PMCID： PMC3640403          DOI： 10.1111/j.1360-0443.2011.03696.x

Source DB:  PubMed          Journal:  Addiction        ISSN： 0965-2140            Impact factor:   6.526


× No keyword cloud information.
  8 in total

Review 1.  Mechanisms of analgesia by gabapentin and pregabalin--calcium channel alpha2-delta [Cavalpha2-delta] ligands.

Authors:  Charles P Taylor
Journal:  Pain       Date:  2009-01-06       Impact factor: 6.961

Review 2.  The placebo response in clinical trials: more questions than answers.

Authors:  Paul Enck; Sibylle Klosterhalfen; Katja Weimer; Björn Horing; Stephan Zipfel
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-06-27       Impact factor: 6.237

3.  Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence.

Authors:  Walter Ling; Steven Shoptaw; Maureen Hillhouse; Michelle A Bholat; Charles Charuvastra; Keith Heinzerling; David Chim; Jeffrey Annon; Patrick T Dowling; Geetha Doraimani
Journal:  Addiction       Date:  2011-11-15       Impact factor: 6.526

4.  Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials.

Authors:  Craig H Mallinckrodt; Roy N Tamura; Yoko Tanaka
Journal:  J Psychiatr Res       Date:  2011-03-31       Impact factor: 4.791

5.  Comparative anticholinergic activities of 10 histamine H1 receptor antagonists in two functional models.

Authors:  Raymond F Orzechowski; Debra S Currie; Cathryn A Valancius
Journal:  Eur J Pharmacol       Date:  2004-11-30       Impact factor: 4.432

Review 6.  Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA.

Authors:  John R Atack
Journal:  Pharmacol Ther       Date:  2009-09-19       Impact factor: 12.310

7.  A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence.

Authors:  Harold C Urschel; Larry L Hanselka; Michael Baron
Journal:  J Psychopharmacol       Date:  2009-11-25       Impact factor: 4.153

8.  Co-occurring amphetamine use and associated medical and psychiatric comorbidity among opioid-dependent adults: results from the Clinical Trials Network.

Authors:  Daniel J Pilowsky; Li-Tzy Wu; Bruce Burchett; Dan G Blazer; George E Woody; Walter Ling
Journal:  Subst Abuse Rehabil       Date:  2011-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.